In chronic lymphocytic leukemia (CLL), different studies reported a lower incidence (5–11%) of SF3B1 mutations at diagnosis, which increased with therapy resistance to 15–20% (1, 2), and an association with poor prognosis (3, 4). Here, SF3B1 is linked to B-cell chronic lymphocytic leukemia.